Login to Your Account

Industry's Second Put/Call Alliance

GSK Buying Theravance Chunk, Paying $129M In Widened Deal

By Randall Osborne

Thursday, April 1, 2004
With their deal for respiratory diseases already having reached Phase II trials, Theravance Inc. and GlaxoSmithKline plc said they are broadening their relationship to the tune of $129 million, of which a "significant" portion involves GSK upping its ownership of Theravance from 6 percent to 19 percent - and GSK could end up with as much as 60 percent in 2007. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription